# of Displayed Technologies: 30 / 97

Applied Category Filter (Click To Remove): Therapeutics


Categories

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

Peptide-based inhibitor of host factor involved in HIV-1 replication
TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…
  • College: College of Arts & Sciences
  • Inventors: Musier-Forsyth, Karin; Tang, Yingke
  • Licensing Officer: Willson, Christopher

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Willson, Christopher

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Schultz, Teri

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Schultz, Teri

Combination B Cell Epitope Vaccines for Cancer Treatment
TS-064843 — , T2022-244, T2020-109 : Cancer vaccines targeting a combination of B Cell epitopes to improve patient outcomes.
The Need Despite the clinical success of checkpoint receptor blockade in various cancer subtypes, many patients develop resistance, presenting a pressing need for novel approaches. Current inhibitors, like PD-1/PD-L1 and HER-2 exhibit limited efficacy and significant toxicities, underscoring the d…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Dahlman, Jason "Jay"

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
  • Licensing Officer: Dahlman, Jason "Jay"

Small molecules that suppress heat/pain perception
TS-064187 — The Need In the culinary and pharmaceutical realms, the need for a groundbreaking solution to modulate flavor and alleviate sensory perceptions is crucial. Businesses seek innovative ways to enhance consumer experiences by addressing pungency in foods and alleviating burn or pain sensations in phar…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Peterson, Devin; borcherding, Joel
  • Licensing Officer: Dahlman, Jason "Jay"

Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings. The Need The rise of these resilient multi-drug resistant bacteria has …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Schultz, Teri

Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
  • College: College of Engineering (COE)
  • Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
  • Licensing Officer: Schultz, Teri

Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart. The Need In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
  • College: College of Medicine (COM)
  • Inventors: Lewandowski, E. Douglas; Carley, Andrew
  • Licensing Officer: Schultz, Teri

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
  • College: College of Medicine (COM)
  • Inventors: Tedeschi, Andrea
  • Licensing Officer: Schultz, Teri

Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males. The Need Despite the crucial role of androgen receptors (AR) in HCC progress…
  • College: College of Pharmacy
  • Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
  • Licensing Officer: Schultz, Teri

Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
  • College: College of Medicine (COM)
  • Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
  • Licensing Officer: Bhatti, Hamid

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Taysavang, Panya

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
  • College: College of Medicine (COM)
  • Inventors: Chu, Nam; Le, Nhat
  • Licensing Officer: Taysavang, Panya

Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
  • Licensing Officer: Schworer, Adam

Underwater Zooplankton Enhancing Light Array (UZELA); A Novel Device for Stimulating Nutritional Therapy in Corals
TS-062571 — The Need Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…
  • College: College of Arts & Sciences
  • Inventors: Grottoli, Andrea; Dixon, Shannon; Hulver, Ann Marie; Jackson, Eric; Shea, Ryan; Steck, James
  • Licensing Officer: Willson, Christopher

Purification of apoproteins and general methods for protein purification
TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.
The Need Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable sol…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Schworer, Adam

Show More Technologies

Loading icon